Gynecologic Cancer
Gynecologic Cancer
Advertisement
Rob DillardGynecologic Cancer | October 3, 2024
A study identified possible prognostic factors and survival patterns based on histology type in endometrial cancer patients.
Read More
Rob DillardBreast Cancer | September 26, 2024
A study analyzed the correlation between cancer-related cognitive impairment and neurotransmission pathways.
Dr. Andrew HertlerGynecologic Cancer | September 4, 2024
Dr. Andrew Hertler explains why health disparities exist for Black women with ovarian cancer.
Rob DillardGynecologic Cancer | August 20, 2024
Sexual counseling training in gynecological cancers is effective at generating increased awareness among midwifery students.
Rob DillardGynecologic Cancer | August 5, 2024
The FDA approved dostarlimab-gxly with carboplatin and paclitaxel for endometrial cancer.
Rob DillardGynecologic Cancer | June 21, 2024
The FDA approved pembrolizumab with chemotherapy for adult patients with primary advanced, recurrent endometrial carcinoma.
Rob DillardASCO 2024 | June 4, 2024
Pembrolizumab use is increasing among patients with recurrent cervical cancer.
Rob DillardASCO 2024 | May 30, 2024
An objective manual screening process may enhance diversity in gynecologic cancer clinical trial enrollment.
Rob DillardCervical Cancer | May 14, 2024
Camrelizumab plus apatinib demonstrates robust and sustained efficacy in treating patients with advanced cervical cancer.
Rob DillardGynecologic Cancer | May 3, 2024
The FDA granted approval to tisotumab vedotin-tftv for the treatment of recurrent or metastatic cervical cancer.
Rob DillardGynecologic Cancer | April 24, 2024
The addition of dostarlimab to platinum chemotherapy is cost effective and significantly improves QOL.
Rob DillardGynecologic Cancer | April 10, 2024
A blood-based machine learning assay may be able to differentiate patients with ovarian cancer from healthy patients.
Rob DillardGynecologic Cancer | January 10, 2024
According to a retrospective study, a high preoperative CONUT score indicates poor prognosis in cervical cancer.
Patrick DalyOncology | June 30, 2023
According to a report, published in the Journal of Contemporary Brachytherapy, patients with gynecologic malignancies ...
Kerri FitzgeraldOncology | August 31, 2023
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
DocWire News EditorsOvarian Cancer | April 11, 2023
Fragmentation of care is associated with an increased risk for adverse outcomes, but data are limited on this topic in ...
DocWire News EditorsSpring 2019 Conference coverage | April 10, 2023
Among female cancer patients, obesity and low levels of physical activity may be associated with increased inflammation ...
DocWire News EditorsSpring 2019 Conference coverage | August 28, 2023
2019 Society of Gynecologic Oncology Annual Meeting, there were no significant differences in outcomes based on age ...
Kerri FitzgeraldGynecologic Cancer | August 30, 2023
According to the Centers for Disease Control and Prevention (CDC), uterine cancer incidence and mortality is on the ...
Kaitlyn D’OnofrioVTE | August 30, 2023
Patients with uterine serous carcinoma are at an increased risk of developing venous thromboembolism (VTE) not just ...
Advertisement
Advertisement
Advertisement
Latest News

October 8, 2024